) -- Adam Feuerstein's take on the biotech week that ended Nov. 12, 2010:
The week's best-performing stocks in the sector:
(APPY - Get Report)
Is it any coincidence that Aastrom filed a $75 million mixed shelf registration Friday?
Human Genome Sciences
FDA Reviews Lupus Drug
The week's worst-performing stocks:
(SRDX - Get Report)
sold 11.5 million shares at $8, raising $86 million to fund commercial launch of Ofirmev, a hospital-based intravenous form of acetameniphan.
> > Bull or Bear? Vote in Our Poll
(ATHX - Get Report)
received FDA clearance to start phase II study of Multistem stem cell therapy for inflammatory bowel disease.
'Marginal' Obesity Drug Now Unsafe?
Research abstracts for
American Society of Hematology
annual meeting were
priced 7.37 million stock units (stock and warrants) at $2.85 a unit, raising $20 million.
to begin human clinical trials of antibiotic PMX-30063.
Drags Feet on U.S. Approval Filing
filed for FDA approval of an expansion to its Provenge manufacturing plant in New Jersey, while the Centers for Medicare and Medicaid (CMS) released the technical assessment of Dendreon's Provenge ahead of next week's National Coverage Determination meeting.
sold 9.9 million shares at $7.30, raising $72 million.
Biotech Stock Mailbag
, Arena Pharmaceuticals,
, and Osiris Therapeutics.
preview of next week's important regulatory meetings
facing Human Genome Sciences, Dendreon and
Human Genome: Benlysta FDA Panel Preview
Lawyer Indicted for Obstructing the FDA
European Drug Approval Agency Looking for new leader
(via invivo blog)
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to: